![Alliance News](https://static.lse.co.uk/images/news-logos/alliance-news-logo.png)
Avacta To Raise GBP48 Million To Accelerate Development Of Therapies
Avacta To Raise GBP48 Million To Accelerate Development Of Therapies
Read moreThu, 22nd Sep 2016 15:56
Avacta To Raise GBP48 Million To Accelerate Development Of Therapies
Read more(Sharecast News) - Biotherapeutic and reagent developer Avacta Group announced its intention to raise up to £45m through a placing to institutional and other investors, a direct subscription with the company, and offers to retail and other investors via the PrimaryBid platform, it announced on Thursday.
Read more(Sharecast News) - Avacta Group has entered into an exclusive distribution agreement with Medusa19 for direct-to-consumer sales of a saliva-based rapid test for the Covid-19 antigen, it announced on Wednesday.
Read moreUK TRADING UPDATE SUMMARY: Blencowe And BlueRock Recommence Operations
Read more(Sharecast News) - Biotherapeutics developer Avacta Group shipped out reagents for Covid-19 antigen testing to its diagnostic test development partners on Monday.
Read moreAvacta Group Reports Widened Loss Amid Higher Operating Expenses
Read moreUK TRADING UPDATE SUMMARY: Avacta, Genedrive Progress With Virus Tests
Read more(Sharecast News) - Biotherapeutics developer Avacta has entered into a collaboration agreement with American firm Adeptrix to develop a high throughput Covid-19 antigen test using its proprietary bead-assisted mass spectrometry (BAMS) platform.
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreUK TRADING UPDATE SUMMARY: BATM Gets EUR29 Million Ventilator Order
Read more(Sharecast News) - Avacta Group said on Wednesday that, in four weeks and "well ahead" of schedule, it had successfully generated multiple 'Affimer' reagents that bound the SARS-COV-2 viral antigen as part of the collaboration with Cytiva - formerly GE Healthcare Life Sciences - to develop an Affimer-based rapid test for the Covid-19 coronavirus infection.
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreAvacta To Co-Develop Test That Can Diagnose Covid-19 In Minutes
Read moreAvacta Raises More-Than-Expected GBP3.8 Million In Share Placing
Read more(Sharecast News) - Biotherapeutics company Avacta Group announced on Monday that, in response to "substantial" institutional interest, it has conditionally raised gross proceeds of ?3.75m under a placing, through the issue of 20,833,333 new ordinary shares at a price of 18p each.
Read more